SCHEMBL3943244

SCHEMBL3943244

CNC(=O)c1ccc2c(OC)c(C)c(C(=O)c3ccc(N)c(C(=O)O)c3)n2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 6/20 0.37
▸ HDAC1 Q13547 6/20 0.37
▸ RAF1 P04049 1/20 0.37
▸ ARAF P10398 1/20 0.37
▸ HDAC3 O15379 3/20 0.34
▸ HDAC4 P56524 3/20 0.34
▸ HDAC7 Q8WUI4 3/20 0.34
▸ HDAC2 Q92769 3/20 0.34
▸ HDAC10 Q969S8 3/20 0.34
▸ HDAC11 Q96DB2 3/20 0.34
▸ HDAC8 Q9BY41 3/20 0.34
▸ HDAC6 Q9UBN7 3/20 0.34
▸ HDAC9 Q9UKV0 3/20 0.34
▸ HDAC5 Q9UQL6 3/20 0.34
▸ MAPT P10636 1/20 0.33
▸ HNF4A P41235 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ TUBB4A P04350 1/20 0.33
▸ TUBB P07437 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1573306 0.87 POLB (0.36) MAPTHNF4AALDH1A1POLBTUBB4A
SCHEMBL3947583 0.87 ALDH1A1 (0.36) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL145931 0.81 HTT (0.45) MAPTALDH1A1
SCHEMBL1573145 0.81 RARB (0.34) MAPTALDH1A1KDM4E
SCHEMBL1573088 0.81 RARB (0.34) MAPTALDH1A1KDM4E
SCHEMBL1573232 0.81 ALDH1A1 (0.33) MAPTALDH1A1KDM4E
SCHEMBL3954660 0.81 HTT (0.44) MAPTALDH1A1
SCHEMBL3946003 0.80 TUBB4A (0.43) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4503822 0.80 KDM4E (0.38) MAPTALDH1A1POLBTUBB4ATUBB
Water SCHEMBL4620128 0.80 HTT (0.43) MAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553845-B2 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives SANOFI-AVENTIS (FR) 2009-06-30 — — US claimed
US-7553845-B2 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives SANOFI-AVENTIS (FR) 2009-06-30 — — US disclosed
US-20060199962-A1 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives SANOFI-AVENTIS (FR) 2006-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199962-A1 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives FGF1, FGF2, FGFR1 BRAF 704/4885HDAC1 527/4885RAF1 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback